Synapse - Works

Results (115372)

ASC2ESCALATE: A phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Meeting Abstract

Sasaki, K.; Mauro, M.; Levy, M. Y.; Atallah, E. L.; Koller, P. B.; Maegawa, R.; Damon, A.; Kumar, J.; Khan, M.; Cortes, J. E.
Blood (2022)

Fulltext@MSK | Save

First-in-human study of Elvn-001, a highly selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed previous tyrosine kinase inhibitor therapies

Meeting Abstract

Hughes, T.; Mauro, M.; Branford, S.; Deng, W.; Wang, Q.; Collins, H.; Hochhaus, A.
Blood (2022)

Fulltext@MSK | Save

Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E.; Mauro, M.; Rampal, R. K.; Bose, P.
Blood (2022)

Fulltext@MSK | Save

Dynamics of response and response factors in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase 3 Ascembl study

Meeting Abstract

Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Mauro, M.; Cortes, J. E.; Apperley, J. F.; García Gutiérrez, V.; Kapoor, S.; Allepuz, A.; more...
Blood (2022)

Fulltext@MSK | Save

Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) in terms of second line (2L) treatment: An ad hoc analysis from the POLARIX study

Meeting Abstract

Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; Ho, R.; more...
Blood (2022)

Fulltext@MSK | Save

Radiotherapy for secondary CNS lymphoma: Patterns of utilization and clinical outcomes

Meeting Abstract

Cederquist, G. Y.; Tringale, K. R.; Hajj, C.; Hubbeling, H.; Fregonese, B.; Lee, J.; Scordo, M.; Grommes, C.; Yahalom, J.; Imber, B. S.
Blood (2022)

Fulltext@MSK | Save

The second generation type II JAK2 inhibitor, AJ1-10502, demonstrates enhanced selectivity, improved therapeutic efficacy and reduced mutant cell fraction compared to type I JAK2 inhibitors in models of myeloproliferative neoplasms (MPNs)

Meeting Abstract

Rai, S.; Stetka, J.; Usart, M.; Hao-Shen, H.; Park, Y.; Houston, R.; Martinez Benitez, A. R.; Wereski, M.; Guzzardi, E.; Persaud, S.; more...
Blood (2022)

Fulltext@MSK | Save

L-Mind: A safety and efficacy analysis of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving treatment for at least 2 years

Meeting Abstract

Duell, J.; Jurczak, W.; Liberati, A. M.; Halka, J.; Pena Carbó, E.; Abrisqueta Costa, P.; Maddocks, K. J.; Dreyling, M.; Rosenwald, A.; Bakuli, A.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 1a/b dose escalation study of the BTK/FLT3 inhibitor luxeptinib in patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Samaniego, F.; Sadiq, A. A.; Mahadevan, D.; Koontz, M. Z.; Villasboas, J. C.; Burke, J. M.; Reid, E. G.; Cherry, M.; Melear, J.; Priego, V.; more...
Blood (2022)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in patients with diffuse large B-cell lymphoma (DLBCL) treated with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in the phase III POLARIX study

Meeting Abstract

Friedberg, J. W.; Thompson, C. A.; Trněný, M.; Morschhauser, F.; Salles, G.; Reagan, P. M.; Hertzberg, M.; Smolewski, P.; Zhang, H.; Thieblemont, C.; more...
Blood (2022)

Fulltext@MSK | Save